ZDHHC9 as a Potential Biomarker for Prognostic Evaluation and Diagnostic Identification in BRCA, CESC, HNSC, and KIRP Tumors

An expanding corpus of evidence suggests that zinc finger DHHC‐type palmitoyltransferase 9 (ZDHHC9) may represent a promising biomarker in various malignancies. Noteworthy is the fact that ZDHHC9 has been discovered to be significantly upregulated in specific varieties of human gastrointestinal cancers. Nevertheless, the precise role it plays in tumor prognostic evaluation and diagnostic identification remains ambiguous. In this study, we commenced with a thorough investigation of ZDHHC9 expression by leveraging the extensive and comprehensive TCGA database. This resource offers a wealth of valuable information and data samples, which enabled a more comprehensive and thorough analysis. The expression levels of ZDHHC9 in BRCA, CESC, HNSC, and KIRP were thoroughly investigated, revealing a significant elevation compared to normal tissues. This significant escalation was observed to be intimately linked with an adverse prognosis. A comprehensive analysis of the data revealed that the increased expression of ZDHHC9 in these particular cancer types was associated with poorer outcomes for patients. The extensive study examining various cancer types has yielded significant insights regarding the function of ZDHHC9, as well as its potential implications for prognosis and therapeutic strategies. Functional predictions indicate that immune or metabolic disorders, as well as the activation of carcinogenic signaling pathways due to abnormal expression of ZDHHC9, may significantly contribute to tumor progression and poor prognosis in patients. This further corroborates the influence of ZDHHC9 on the migration and invasion capabilities of CESC cell lines. ZDHHC9 is a key target for therapeutic and diagnostic use in BRCA, CESC, HNSC, and KIRP tumors, contributing significantly to the understanding of molecular tumor treatments.